Induced Depressive Disorder Following the First Dose of COVID-19
Vaccine

Ismail      Rammouz; Jalal      Doufik; Rachid      Aalouane; Saïd      Boujraf

doi:10.2174/1871527321666220829112733

Abstract

Introduction: Several COVID-19 vaccines have been implemented. However, some side effects of the vaccine have been reported, which are sometimes very harmful. Reported cases and data are still very limited regarding the psychiatric side effects of the COVID-19 vaccine. To our knowledge, only one case has been reported. In this paper, we report the case of a patient who presented an acute depressive episode 24 hours after receiving his first dose of the BNT162b2mRNA vaccine.

Case Report: The case was a 26-year-old man with a history of Down syndrome with moderately good autonomy for daily routine tasks. The patient, who presented hypothyroidism at 10 years old and schizophrenia at 15 years old, was doing well before the vaccination and received his first dose of the BNT162b2mRNA vaccine. Twenty-four hours later, he presented depressive symptoms that resolved spontaneously after one week. Then, fifteen days later, the symptoms reappeared, and the episode lasted for 5 weeks. The patient received 10 mg/day of escitalopram besides his usual treatment. The depressive symptoms improved considerably by the second day of treatment.

Discussion: The presented case illustrated significant diagnostic challenges, especially when taking into account the sequential relationship between the COVID-19 vaccine and the occurrence of depressive symptoms. A single case of depression has been reported after the administration of the COVID-19 vaccine. Scientific evidence suggests the important role of the immune system in the pathophysiology of various psychiatric disorders, including depression.

Conclusion: Health professionals must take into consideration the potential psychiatric side effects even being rare so far, especially in vulnerable subjects. Further studies are required to establish the causal effects of depressive symptoms occurring during the weeks following the COVID-19 vaccine bolus injection.

Keywords: Side effects, vaccine, BNT162b2mRNA, COVID-19, depression, co-morbidities.

« Previous

[1]
Marshall M, Ferguson ID, Lewis P, et al. Symptomatic acute myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19 vaccination. Pediatrics  2021; 148(3): e2021052478.
 [http://dx.doi.org/10.1542/peds.2021-052478] [PMID: 34088762]

[2]
Lee EJ, Cines DB, Gernsheimer T, et al. Thrombocytopenia following Pfizer and Moderna SARS‐CoV ‐2 vaccination. Am J Hematol  2021; 96(5): 534-7.
 [http://dx.doi.org/10.1002/ajh.26132] [PMID: 33606296]

[3]
McMahon DE, Amerson E, Rosenbach M, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases. J Am Acad Dermatol  2021; 85(1): 46-55.
 [http://dx.doi.org/10.1016/j.jaad.2021.03.092] [PMID: 33838206]

[4]
Uvais NA. Depression following ChAdOx1-S/nCoV-19 vaccine. Eur J Psychiatry  2022; 36(2): 140-1.
 [http://dx.doi.org/10.1016/j.ejpsy.2021.08.001] [PMID: 34608345]

[5]
Veer IM, Riepenhausen A, Zerban M, et al. Psycho-social factors associated with mental resilience in the corona lockdown. Transl Psychiatry  2021; 11(1): 67.
 [http://dx.doi.org/10.1038/s41398-020-01150-4] [PMID: 33479211]

[6]
Lu L, Xiong W, Mu J, et al. The potential neurological effect of the COVID-19 vaccines: A review. Acta Neurol Scand  2021; 144(1): 3-12.
 [http://dx.doi.org/10.1111/ane.13417] [PMID: 33779985]

[7]
Yesilkaya UH, Sen M, Tasdemir BG. A novel adverse effect of the BNT162b2 mRNA vaccine: First episode of acute mania with psychotic features. Brain Behav Immun Health  2021; 18: 100363.
 [http://dx.doi.org/10.1016/j.bbih.2021.100363] [PMID: 34632429]

[8]
Guo X, Jiang K. Is Depression the result of immune system abnormalities? Shanghai Jingshen Yixue  2017; 29(3): 171-3.
 [http://dx.doi.org/10.11919/j.issn.1002-0829.217015] [PMID: 28904512]

[9]
Sharpley AL, Cooper CM, Williams C, Godlewska BR, Cowen PJ. Effects of typhoid vaccine on inflammation and sleep in healthy participants: A double-blind, placebo-controlled, crossover study. Psychopharmacology (Berl)  2016; 233(18): 3429-35.
 [http://dx.doi.org/10.1007/s00213-016-4381-z] [PMID: 27503474]

[10]
Kuhlman KR, Robles TF, Dooley LN, Boyle CC, Haydon MD, Bower JE. Within-subject associations between inflammation and features of depression: Using the flu vaccine as a mild inflammatory stimulus. Brain Behav Immun  2018; 69: 540-7.
 [http://dx.doi.org/10.1016/j.bbi.2018.02.001] [PMID: 29458196]

[11]
Collacott RA, Cooper SA, McGrother C. Differential rates of psychiatric disorders in adults with Down’s syndrome compared with other mentally handicapped adults. Br J Psychiatry  1992; 161(5): 671-4.
 [http://dx.doi.org/10.1192/bjp.161.5.671] [PMID: 1422617]

[12]
Walker JC, Dosen A, Buitelaar JK, Janzing JGE. Depression in Down syndrome: A review of the literature. Res Dev Disabil  2011; 32(5): 1432-40.
 [http://dx.doi.org/10.1016/j.ridd.2011.02.010] [PMID: 21392935]

[13]
Bode H, Ivens B, Bschor T, Schwarzer G, Henssler J, Baethge C. Association of hypothyroidism and clinical depression. JAMA Psychiatry  2021; 78(12): 1375-83.
 [http://dx.doi.org/10.1001/jamapsychiatry.2021.2506] [PMID: 34524390]

Rights & Permissions Print Cite

Article Metrics

5

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1871527321666220829112733	Print ISSN 1871-5273
Publisher Name Bentham Science Publisher	Online ISSN 1996-3181

CNS & Neurological Disorders - Drug Targets

Induced Depressive Disorder Following the First Dose of COVID-19 Vaccine

Abstract Play Pause

Related Journals

Related Books

Abstract